الفهرس 
Introduction and RationaleOnly 14 pages are availabe for public view
 |  | from | 101 |  |  |
| | | from | 101 | | |
Abstract
Breast cancer is the most common cancer in women worldwide.(1) About 70% of breast cancer is estrogen receptor-positive.(2) Premenopausal women has to be given special consideration as they tend to have higher risk of advanced disease at presentation.(3)
Based on the results of the SOFT and TEXT trials, the American Society of Clinical Oncology recommended that premenopausal women with estrogen receptor-positive breast cancer will benefit from OS in conjunction with adjuvant endocrine therapy and it became the standard of care.(7)
Recent studies showed that about 25% of patients did not achieve adequate OS at 3 months while on ovarian suppression therapy. About 17% of patients did not achieve adequate OS even at 12 months.(8) The clinical importance of this remains unclear, but failure to achieve maximally suppressed estradiol levels could theoretically contribute to poorer outcomes for ER+ breast cancer patients.
We conducted a retrospective study evaluating the proportion of persistent OE in premenopausal, estrogen-receptor positive breast cancer patients on OS therapy and its correlation to baseline clinical data and early clinical outcomes. We included 143 patients attending clinical oncology department in Suez Canal University Hospital. Patients included were more than 18 years old with stage I-III estrogen receptor-positive breast cancer. Patients